Table 1 Circular RNAs implicated in hematological malignancies
From: The functions and clinical significance of circRNAs in hematological malignancies
Disease | CircRNA | Expression | Phenotype | Clinical significance | Possible target/mechanism | Ref. |
|---|---|---|---|---|---|---|
AML | circRNA-DLEU2 | Up | proliferation ( +), apoptosis (−), tumor formation ( +) | / | miR-496/PRKACB | [125] |
circ_100290 | Up | proliferation ( +), apoptosis (−) | / | miR-203/Rab10 | [23] | |
circPAN3 | Up | autophagy ( +), apoptosis (−), ADM-resistance ( +) | / | miR-153-5p/miR-183-5p/XIAP | ||
circ-ANXA2 | Up | proliferation ( +), apoptosis (−) | high disease risk, poor risk stratification, low CR level, short EFS and OS | miR-23a-5p/miR-503-3p | [105] | |
circ_0009910 | Up | proliferation ( +), apoptosis (−) | poor risk, short OS | miR-20a-5p | [19] | |
circ_0000370 | Up | proliferation ( +), apoptosis (−), cell cycle ( +) | FLT3-ITD +  | miR-1299/S100A7A | [26] | |
circMYBL2 | Up | proliferation ( +), quizartinib resistance ( +) | FLT3-ITD +  | PTBP1, FLT3 kinase translational ( +) | [25] | |
circ-VIM | Up | / | distribution of WBC count, FAB subtypes, short OS and LFS | / | [106] | |
circ-0004136 | Up | proliferation ( +) | / | miR-142 | [21] | |
circ-HIPK2 | Down | differentiation ( +) | ATRA-induced differentiation | miR-124-3p | [111] | |
circ_0001947 | Down | proliferation (−), apoptosis ( +) | white blood cell, hemoglobin, diagnosis, prognosis | miR-329-5p/CREBRF | [22] | |
circ_0121582 | Down | proliferation (−) | / | miR-224/GSK3β, TET1/GSK3β/Wnt/β-catenin | [24] | |
CML | circ_0080145 | Up | proliferation ( +) | / | sponge miR-29b | [20] |
circ_0009910 | Up | proliferation ( +), autophagy ( +), apoptosis (−) | imatinib resistance, short OS | miR-34a-5p/UKL1 | [47] | |
circBA9.3 | Up | proliferation ( +), apoptosis (−) | TKI-resistance | c-ABL1 & BCR-ABL1 level ( +) | [45] | |
circ_100053 | Up | / | clinical stage, BCR/ABL mutant status, short OS, imatinib resistance | / | [46] | |
circ_0080145 | Up | proliferation ( +), glycolysis ( +), apoptosis (−) | IM-resistance | miR-326/PPFIA1 | [15] | |
ALL | circPVT1 | Up | proliferation ( +), apoptosis (−) | / | c-Myc & Bcl-2 expression ( +) | [27] |
circAF4 | Up | apoptosis (−), leukemogenesis ( +) | risk stratification | miR-128-3p/MLL-AF4 | [96] | |
CLL | circ-CBFB | Up | progression ( +), apoptosis (−) | diagnosis, low survival time, independent predictor of prognosis | miR-607/FZD3/Wnt/β-catenin pathway | [31] |
circ-RPL15 | Up | proliferation ( +) | IGHV mutation status | miR-146b-3p/RAS/RAF1/MEK/ERK pathway | [108] | |
circ_0132266 | Down | proliferation (−), apoptosis ( +) | / | miR-337-3p/PML | [30] | |
DLBCL | circ-APC | Down | proliferation (−), cell cycle (−) | Ann Arbor stage, CHOP-like and rituximab resistance, short OS, independent prognostic factor | miR-888/APC, TET1/APC, inactivate Wnt/β-catenin pathway | [33] |
MCL | circCDYL | Up | proliferation ( +) | diagnosis |  | [34] |
T-LBL | circ-LAMP1 | Up | proliferation ( +), apoptosis (−) | / | miR-615-5p/DDR2 | [32] |
MM | circ_0007841 | Up | proliferation ( +) | clinical type, cytogenetic mutation, bone destruction, R-ISS staging, DOX resistance | ABCG2 level ( +) | [49] |
circCDYL | Up | DNA synthesis ( +), apoptosis (-) | ISS and DS stage, diagnosis, short OS | miR-1180/YAP | [35] | |
circ_0000190 | Down | proliferation (−), apoptosis ( +), tumor growth (−) | ISS and DS stage, high risk, short PFS, OS | miR-767-5p/MAPK pathway | [37] | |
circ-SMARCA5 | Down | proliferation (−), apoptosis ( +) | β2-MG level, ISS stage, short PFS and OS | miR-767-5p | [126] |